The endochondral bone protein CHM1 maintains an undifferentiated, invasive phenotype in Ewing sarcoma.
Von Heyking K, Calzada-Wack J, Neff F, (...), Burdach S, Richter GHS.
(Submission Dec 2015).
---> WP1.5

The posterior HOXD locus: Its contribution to malignancy of Ewing sarcoma.
Von Heyking K, Roth L, Ertl M., (...), Burdach S, Richter GHS.
(Submission Nov 2015).
---> WP1.5

TMA inspiration: Decode interdependencies in multi-factorial tissue microarray data.
Boecker F, Buerger H, Mallela N. V., Korsching E.
Algorithms Mol Biol. (submitted)
---> P3

Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.
Schirmer D, Grünewald T, Klar R, (...), Thiel U, (...), Burdach S, Richter GHS.
---> WP1.5, 2.5

Promises and challenges of Smac mimetics as cancer therapeutics.
Fulda S.
Clin Cancer Res (in press)
---> WP1.4

Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma.
Heinicke U, Kupka J, Fichter I, Fulda S.
Oncogene (in press)
---> WP1.4

Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T, Giorgi C, Schmidt O., (...), Schäfer B, Burdach S, Richter GH.
Oncotarget. 2015 Nov25.
---> WP1.5, 1.7

Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma.
Agelopoulos K, Richter GH, Schmidt E, Dirksen U, (...), Kontny U, (...), Poos K, Korsching E, (...), Köhler G, Hartmann W, Wardelmann E, (...), Baumhoer D, Jürgens H, Burdach S, (...), Müller-Tidow C.
Clin Cancer Res. 2015 Nov 1;21(21):4935-46.
---> WP1.1/1.2/1.5/2.3/P2/P3/Coord.

Local control in Ewing sarcoma of the chest wall: Results of the EURO-EWING 99 trial.
Bedetti B, Wiebe K, Ranft A, (...), Jürgens H, Dirksen U.
Ann Surg Oncol. 2015 Sep;22(9):2853-9.
---> Coord.

IL6 secreted by Ewing sarcoma tumor microenvironment confers anit-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells.
Lissat A, Joerschke M, Shinde DA, (...), Kontny U.
BMC Cancer. 2015 Jul 28;15(1):552
---> WP2.3

New small molecules targeting apoptosis and cell viability in osteosarcoma.
Maugg D, Rothenaigner I, Schorpp, Potukuchi HK, Korsching E, Baumhoer D, Hadian K, Smida J, Nathrath M.
PLos One. 2015 Jun 3;10(6).
---> WP1.1/P3

TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
Ribi S, Baumhoer D, Lee K, (...), Smida J, Nathrath M, (...), Hillmer AM.
Oncotarget. 2015 Apr 10;6(10):7727-40.
---> WP1.1

Genomic heterogeneity of osteosarcoma - shift from single candidates to functional modules.
Poos K, Smida J, Maugg D, Eckstein G, Baumhoer D, Nathrath M, Korsching E.
PLoS One. 2015 Apr 7;10(4):e0123082. doi: 10.1371/journal.pone.0123082. eCollection 2015.
---> WP1.1/P3

Targeting apoptosis for anticancer therapy.
Fulda S.
Semin Cancer Biol. 2015 Apr:31:84-8. Epub 2014 May 22.
---> WP1.4

Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.
Selvanathan SP, Graham GT, Erkizan HV, Dirksen U, (...), Toretsky JA.
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1307-16.
---> Coord.

Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R, Borchardt C, Clemens D, Kool M, Dirksen U, Frühwald MC.
Anticancer Drugs. 2015 Mar;26(3):301-11.
---> Coord.

Gene expression profiling of Ewing sarcoma tumours reveals the prognostic importance of tumour-stromal interactions: a report from the Children's Oncology Group.
Volchenboum SL, Andrade J, Huang L, (...), Potratz J, Dirksen U, Triche TJ, Lawlor ER..
J Path: Clin Res Month 2015.
---> WP1.6/Coord.

Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
van Maldegem AM, Benson C, Rutkowski P, (...), Juergens H, Dirksen U, Gelderblom H.
Pediatr Blood Cancer. 2015 Jan;62(1):40-4.
---> Coord.


Smac mimetics as IAP antagonists.
Fulda S.
Semin Cell Dev Biol. 2014 Dec 27. pii: S1084-9521 (Epub ahead of print)
---> WP1.4

Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling.
Fulda S.
Mitochondrion. 2014 Nov;19 Pt A:85-7. Epub 2014 Apr 26.
---> WP1.4

Therapeutic exploitation of necroptosis for cancer therapy.
Fulda S.
Semin Cell Dev Biol. 2014 Nov;35:51-6. Epub 2014 Jul 25.
---> WP1.4

Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U, Fulda S.
Cancer Lett. 2014 Aug 28;351(1):50-8. Epub 2014 May 6.
---> WP1.4

Cyclophosphamide compared with Ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: Results of the randomized noninferiority Euro-EWING99-R1 trial.
Le Deley MC, Paulussen M, Lewis I, (...), Juergens H, (...), Dirksen U.
J Clin Oncol. 2014 Aug 10;32(23):2440-8.
---> Coord.
---> "Research for Rare" Paper of the month June 2014

A Rb1 promoter variant with reduced activity contributes to osteosarcoma susceptibility in irradiated mice.
Rosemann M, Gonzalez-Vasconcellos I, Domke T, (...), Nathrath M, Atkinson MJ.
Mol Cancer. 2014 Aug 4;13:182.
---> WP1.1

Molecular pathways: targeting death receptors and smac mimetics.
Fulda S.
Clin Cancer Res. 2014 Aug 1;20(15):3915-20.
---> WP1.4

Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities.
Specht K, Sung YS, Richter GH, Fletcher CD, Antonescu CR.
Genes Chromosomes Cancer. 2014 Jul;53(7):622-33.
---> WP1.5

Structuring osteosarcoma knowledge: an osteosarcoma-gene association database based on literature mining and manual annotation.
Poos K, Smida J, Nathrath M, Maugg D, Baumhoer D, Neumann A, Korsching E.
Database (Oxford). 2014 May 27;2014. pii: bau042.
---> WP1.1/P3

Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma - reasons and consequences.
Arabi L, Gsponer JR, Smida J, Nathrath M, (...), Baumhoer D.
Genes Cancer. 2014 Apr;5(1-2):56-63.
---> WP1.1

The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma.
Rasper M, Jabar S, Ranft A, Jürgens H, Amler S, Dirksen U.
Pediatr Blood Cancer. 2014 Apr 11. doi: 10.1002/pbc.25042 (Epub ahead of print).
---> Coord.

Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: Low miR-31 expression with effects on proliferation and invasion.
Karnuth B, Dedy N, Spiker T, (...), Dirksen U, Jürgens H, Bräuninger A.
PLoS One. 2014 Mar 25;9(3):e93067.
---> Coord.

Osteosarcomas of the jaws differ from their peripheral counterparts and require a distinct treatment approach. Experiences from the DOESAK Registry.
Baumhoer D, Brunner P, Eppenberger-Castori S, Smida J, Nathrath M, Jundt G.
---> WP1.1 


Molecular pathways: Targeting inhibitor of apoptosis proteins in cancer - from molecular mechanism to therapeutic application.
Fulda S.
Clin Cancer Res. 2014 Jan 15;20(2):289-95. Epub 2013 Nov 22.
---> WP 1.4

Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system.
Unland R, Kerl K, Schlosser S, (...), Richter GH, (...), Frühwald MC.
J Neurooncol. 2014 Jan;116(2):237-49. Epub 2013 Nov 22.
---> WP 1.3/1.5

Osteosarcomas of the jaws differ from their peripheral counterparts and require a distinct treatment approach. Experiences from the DOESAK Registry.
Baumhoer D, Brunner P, Eppenberger-Castori S, Smida J, Nathrath M, Jundt G.
Oral Oncol. 2014 Feb;50(2):147-53. Epub 2013 Nov 15.
---> WP 1.1

Pelvic reconstruction with compound osteosynthesis following hemipelvectomy: A clinical study.
Gebert C, Wessling M, Gosheger G, (...), Dirksen U, Hardes J.
Bone Joint J. 2013 Oct;95-B(10):1410-6.
---> Coord.

Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment.
Thiel U, Koscielniak E, Blaeschke F, (...), Lang P, Bader P, Burdach S.
Br J Cancer 2013 Nov 12;109(10):2523-32. Epub 2013 Oct 22.
---> WP 2.1/2.4/2.5/P1

Renal Ewing tumors.
Zöllner S, Dirksen U, Jürgens H, Ranft A.
Ann Oncol. 2013 Sep;24(9):2455-61. Epub 2013 Jun 11.
---> Coord.

Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK, Graab U, Fulda S.
Cancer Lett. 2013 Sep 1;337(2):200-9.
---> WP 1.4

Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome in autophagosomal membranes.
Basit F, Christofanon S, Fulda S.
Cell Death Differ. 2013 Sep;20(9):1161-73.
---> WP 1.4

The Zyxin-related protein thyroid receptor interacting protein 6 (TRIP6) is overexpressed in Ewing's sarcoma and promotes migration, invasion and cell growth.
Grunewald TG, Willier S, Janik D, Unland R, (...) Dirksen U, Richter GH, (...), Burdach S, (...).
Biol Cell. 2013 Aug 23. (Epub ahead of print)
---> WP 1.3/1.5/2.5

How microRNA and transcription factor co-regulatory networks affect osteosarcoma cell proliferation.
Poos K, Smida J, Nathrath M, Maugg D, Baumhoer D, Korsching E.
PLoS Comput Biol. 2013 Aug;9(8):e1003210. Epub 2013 Aug 29.
---> WP 1.1/P3

First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Miller IV, Raposo G, Welsch U, (...), Thiel U, (...), Richter GH, Burdach S, Grunewald T.
Biol. Cell. 2013 Jul;105(7):289-303.
---> WP1.5/2.5

BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways.
Rapino F, Jung M, Fulda S.
Oncogene. 2014 Mar 27;33(13):1713-24. Epub 2013 May 6.
---> WP 1.4

Molecular targeted therapies for rhabdomyosarcoma: Focus on hedgehog and apoptosis signaling.
Fulda S.
Klin Padiatr. 2013 May;225(3):115-119. Epub 2013 Apr 26.
---> WP 1.4

G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcoma through PGF and MMP1.
Richter GH, Fasan A, Hauer K, (...), Fulda S, (...), Burdach S.
J Pathol. 2013 May;230(1):70-81. Epub 2013 Mar 14.
---> WP1.4/1.5

Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists.
Fulda S.
Oncogene. 2014 Feb 6;33(6):671-6. Epub 2013 Mar 11.
---> WP 1.4

How to target apoptosis signaling pathways for the treatment of pediatric cancers.
Fulda S.
Front Oncol. 2013 Feb 14;3:22.
---> WP 1.4

Regulation of cell death in cancer - possible implications for immunotherapy.
Fulda S.
Front Oncol. 2013 Feb 21;3:29.
---> WP 1.4

Genomic EWS-FLI1 fusion sequences in Ewing sarcoma resemble breakpoint characteristics of immature lymphoid malignancies.
Berger M, Dirksen U, Braeuninger A, Koehler G, Juergens H, Krumbholz M, Metzler M.
PLoS One. 2013;8(2):e56408. Epub 2013 Feb 18.
---> Coord./P2

Alternative cell death pathways and cell metabolism.
Fulda S.
Int J Cell Biol. 2013;2013:463637. Epub 2013 Jan 21.
---> WP 1.4

Analyzing the basic principles of tissue microarray data measuring the cooperative phenomena of marker proteins in invasive breast cancer.
Buerger H, Boecker F, Packeisen J, Agelopoulos K, Poos K, Nadler W, Korsching E.
Open Access Bioinformatics 2013:5 1-21
---> WP1.2/P3


DKK2 mediates osteolysis, invasiveness and metastatic spread in Ewing Sarcoma.
Hauer K, Calzada-Wack J, Steiger K, (...), Baumhoer D, (...), Burdach S, Richter GH.
Cancer Res. 2012 Nov 30 (Epub ahead of print)
---> WP1.1/1.5

RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis.
Basit F, Humphreys R, Fulda S.
J Biol Chem. 2012 Nov 9;287(46):38767-77. Epub 2012 Aug 27.
---> WP1.4

Human leukocyte antigen distribution in German Caucasians with advanced Ewing's sarcoma.
Thiel U, Wolf P, Wawer A, (...), Klingebiel T, Bader P, (...), Handgretinger R, Lang P, (...) Koscielniak E, (...), Richter GH, (...), Dirksen U, Jürgens H, (...), Burdach S.
Klin Padiatr. 2012 Oct;224(6):353-358. Epub 2012 Jul 20.
---> Coord./WP1.5/WP2.4/WP2.5

Is there 'progression through grade' in ductual invasive breast cancer?
Schymik B, Buerger H, Krämer A, (...), Korsching E.
Breast Cancer Res Treat 2012 Oct;135(3):693-703.
---> P3

Shifting the balance of mitochondrial apoptosis: Therapeutic perspectives.
Fulda S.
Front Oncol. 2012;2:121. Epub 2012 Oct 8.
---> WP1.4

A novel role of IGF1 in Apo2L/TRAIL-mediated apoptosis of Ewing tumor cells.
van Valen F, Harrer H, Hotfilder M, Dirksen U, (...), Jürgens H.
Sarcoma 2012:782970. Epub 2012 Oct 3.
---> Coord./WP1.3

High STEAP1 expression is associated with improved outcome of Ewing's sarcoma patients.
Grunewald T, Ranft A, Esposito I, (...), Baumhoer D, (...), Jürgens H, Dirksen U, Richter GHS, Burdach S.
Ann Oncol. 2012 Aug;23(8):2185-90. Epub 2012 Feb 8.
---> Coord./WP1.1/1.3/1.5

Targeted therapy in Ewing sarcoma.
Lissat A, Chao MM, Kontny U.
ISRN Oncol. 2012;2012:609439. Epub May 28
---> WP2.3

MicroRNA profiling with correlation to gene expression revealed the oncogenic MiR-17-92 cluster to be up-regulated in osteosarcoma.
Baumhoer D, Zillmer S, Unger K, (...), Smida J, Nathrath M.
Cancer Genet. 2012 May;205(5):212-9.
---> WP 1.1

Strong expression of CXCL12 is associated with favorable outcome in osteosarcoma.
Baumhoer D, Smida J, Zillmer S, (...), Nathrath M.
Mod Pathol. 2012 Apr:25(4):522-8. Epub 2011 Dec 16.
---> WP1.1

Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models.
Rettinger E, Meyer V, Kreyenberg H, (...), Koscielniak E, Fulda S, (...), Klingebiel T, Bader P.
Front Oncol. 2012;2:32. Epub 2012 Apr 9
---> WP1.4/2.1/P1

1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, (...), Dirksen U, (...), de Alava E.
Oncogene 2012 Mar 8;31(10):1287-1298
---> Coord.

Site-specific chromatin immunoprecipitation: a selective method to individually analyze neighboring transcription factor binding sites in vivo.
Schuch R, Agelopoulos K, Neumann A, Brandt B, Bürger H, Korsching E.
BMC Res Notes 2012 Feb 20;5:109
---> WP1.2/P3

The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
Rettinger E, Kuci S, Naumann I, (...), Anzaghe M, (...), Klingebiel T, Fulda S, Bader P.
Cytotherapy. 2012 Jan;14(1):91-103. Epub 2011 Oct 6
---> WP1.4/2.1

STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing Tumors.
Grunewald T, Diebold I, Esposito I, (...), Thiel U, (...), Unland R, Müller-Tidow C, (...), Richter GHS, Burdach S.
Mol Cancer Res. 2012 Jan;10(1):52-65. Epub 2011 Nov 11
---> WP1.2/1.3/1.5/2.5


CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients.
Baumhoer D, Elsner M, Smida J, (...), Bielack S, (...), Nathrath M.
Oncotarget. 2011 Dec:2(12):970-5
---> WP1.1/P1

Providing trust and interoperability to federate distributed biobanks.
Lablans M, Bartholomäus S, Ückert F.
Stud Health Technol Inform. 2011;169:213-7
---> P2

Risk of recurrence and survival after relapse in patients with Ewing sarcoma.
Stahl M, Ranft A, Paulussen M, Bölling T, Vieth V, Bielack S, Görtitz I, Braun-Munzinger G, Hardes J, Jürgens H, Dirksen U.
Pediatr Blood Cancer. 2011 Oct;57(4):549-53. Epub 2011 Mar 25
---> Coord./P1

The nature of the characteristic cementum-like matrix deposits in the wall of simple bone cysts.
Baumhoer D, Smida J, Nathrath M, Jundt G.
Histopathology. 2011 Sep:59(3):390-6
---> WP1.1

Schemafreiheit und semantische Interoperabilität: Wege zu einer Metadatenarchitektur für die biomedizinische Forschung.
Bartholomäus S, Lablans M, Roderfeld I, Ückert F.
56. GMDS-Jahrestagung, 26.-29. September, Mainz 2011.
GMS Publishing House; 2011. Doc11gmds436. Published: Sept 20, 2011
---> P2

Grenzen von semantischen Technologien zur Realisierung einer interoperablen Wissensdatenbank.
Roderfeld I, Bartholomäus S, Lablans M, Ückert F.
56. GMDS-Jahrestagung, 26.-29. September, Mainz 2011.
GMS Publishing House; 2011. Doc11gmds503. Published: Sept 20, 2011
---> P2

Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children.
Schlegel P, Teltschik HM, Pfeiffer M, Handgretinger R, Schumm M, Koscielniak E, Feuchtinger T, Klingebiel T, Bader P, Schlegel PG, Greil J, Lang P.
Best Pract Res Clin Haematol. 2011 Sep;24(3):443-52. Epub 2011 Jun 25
---> WP2.1/WP2.4/P1

Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors.
Lang P, Pfeiffer M, Teltschik HM, Schlegel P, Feuchtinger T, Ebinger M, Klingebiel T, Bader P, Schlegel PG, Beck J, Greil J, Handgretinger R.
Best Pract Res Clin Haematol. 2011 Sep;24(3):403-11. Epub 2011 Jun 25
---> WP2.1/WP2.4/P1

Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer.
Hungermann D, Schmidt H, Natrajan R, Tidow N, Poos K, Reis-Filho J S, Brandt B, Bürger H, Korsching E.
J Pathol. 2011 Aug;224(4):517-28. Epub 2011 Jun 27.
---> P3

No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients.
Thiel U, Wawer A, Wolf P, (...), Klingebiel T, (...), Dirksen U, (...), Koscielniak E, (...), Jürgens H, (...), Burdach S; Solid Tumor Working Party (STWP) and the Pediatric Disease Working Party (PDWP) of the European Group for Blood and Marrow Transplantation (EBMT); Asia Pacific Blood and Marrow Transplantation (APBMT); Pediatric Registry for Stem Cell Transplantations (PRST); MetaEICESS Study Group
Ann Oncol. 2011 Jul;22(7):1614-21. Epub 2011 Jan 18
---> Coord./WP1.5/P1

Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.
Baumhoer D, Smida J, (...), Bielack S, Nathrath M.
Hum Pathol. 2011 Jun;42(6):859-66. Epub 2011 Feb 2.
---> WP1.1/P1

Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells.
Thiel U, Pirson S, Müller-Spahn C, (...), Burdach S, Richter GHS.
Br J Cancer. 2011 Mar 15;104(6):948-56


Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children.
Pfeiffer MM, Feuchtinger T, Teltschik HM, Schumm M, Müller, I, Handgretinger R, Lang P.
Haematologica. 2010 Aug;95(8):1381-8. Epub 2010 Feb 9.
---> WP2.4

Genomic Alterations and Allelic Imbalances are Strong Prognostic Predictors in Osteosarcoma.
Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, Remberger K, Korsching E, Scheurlen W, Dierkes C, Burdach S, Jundt G, Atkinson MJ, Nathrath M.
Clin Cancer Res. 2010 Aug 15;16(16):4256-67. Epub 2010 Jul 7
---> WP1.1/WP1.5/P3

Approaching Ewing sarcoma.
Dirksen U, Jürgens H.
Future Oncol. 2010 Jul;6(7):1155-62
---> Coord./WP1.3

Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative EURO-E.W.N.G. 99 trial.
Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslböck M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jürgens H, Kovar H.
J Clin Oncol. 2010 Apr 20;28(12): 1982-8. Epub 2010 Mar 22
---> Coord./WP1.3/P1

Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma:
regulation and phenotypic effects of Hypoxia-Inducible Factor.
Helen J Knowles, Karl-Ludwig Schäfer, Uta Dirksen, Nicholas A Athanasou.
BMC Cancer 2010, 10:372.
---> WP1.3/P2

Efficient lysis of rhabdomyosarcoma cells by cytokine-induced
killer cells: implications for adoptive immunotherapy after
allogeneic stem cell transplantation.
Selim Kuci, Bernhard Voss, Eva Rettinger, Gerrit Weber, Miriam Stais,
Hermann Kreyenberg, Andre Willasch, Zyrafete Kuci, Ewa Koscielniak,
Stephan Klöss, Dorothee von Laer, Thomas Klingebiel, and Peter Bader.
Haematologica 2010.
---> WP2.1


The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES).
Haeusler J, Ranft A, Boelling T, Gosheger G, Braun-Munzinger G, Vieth V, Burdach S, van den Berg H, Juergens H, Dirksen U.
Cancer. 2009 Nov 18. (PDMES)
---> Coord./WP1.3/WP1.5

CD25 blockade protects T cells from activation-induced cell death (AICD) via maintenance of TOSO expression.
Richter, GHS, Mollweide, M, Hanewinkel, K, Zobywalski, C, Burdach, S.
Scand J Immunol. 2009 Sep;70(3):206-15.
---> WP1.5

Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
Burdach S, Plehm S, Unland R, Dirksen U, Borkhardt A, Staege MS, Müller-Tidow C, Richter GH.
Cell Cycle. 2009 Jul 1;8(13):1991-6. Epub 2009 Jul 5.
---> WP1.3/WP1.5

Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases.
S Burdach, U Thiel, M Schöniger, R Haase, A Wawer, M Nathrath, H Kabisch, C Urban, HJ Laws, U Dirksen, M Steinborn, J Dunst and H Jürgens.
Bone Marrow Transplantation (2009), 1-7.
---> Coord./WP1.1/WP1.3/WP1.5

WT1 peptide-specific T cells generated from peripheral blood of healthy donors:
possible implications for adoptive immunotherapy after allogeneic stem cell
G Weber, J Karbach, S Kuci, H Kreyenberg, A Willasch, E Koscielniak, T Tonn, T Klingebiel, WS Wels, E Jaeger and P Bader.
Leukemia (2009) 23, 1634–1642.
----> WP2.1

EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation.
Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I, Quintanilla-Martinez L, Kovar H, Staege MS, Müller-Tidow C, Burdach S.
Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5324-9. Epub 2009 Mar 16.
---> WP 1.3/WP1.5